Alan Schorr, DO
Endocrinology, Diabetes & Metabolism · Langhorne, PANPI 1548263544
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,075 of the $18,425 with a category attached, or 81.8%. Medtronic accounts for 91.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $5,310 and has fallen 77.7% since, to $1,186 in 2025.
Across 116 payments — averaging $158.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Novo Nordisk$365
- Sanofi-aventis U.S. LLC$224
- Intuity Medical Inc$140
- Exact Sciences$124
- Ascensia Diabetes Care US Inc.$106
- plus $657 from 18 others
Across 291 payments — averaging $939.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Senseonics, Incorporated$139K
- Medtronic$123K
- Aspire Bariatrics, Inc.$11K
What the payments were for
- Consulting fees$15,07582%
- Travel & lodging$1,3707%
- Food & beverage$1,6949%
- Education$2852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $16,810 |
| Novo Nordisk | 18 | $365 |
| Sanofi-aventis U.S. LLC | 13 | $224 |
| Intuity Medical Inc | 3 | $140 |
| Exact Sciences | 7 | $124 |
| Ascensia Diabetes Care US Inc. | 2 | $106 |
| Chiasma, Inc. | 1 | $100 |
| Amgen | 4 | $85 |
| Mannkind Corporation | 3 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Lilly USA, LLC | 3 | $43 |
| Shire North American Group Inc | 2 | $39 |
| BD | 2 | $31 |
| AstraZeneca | 2 | $30 |
| IBSA Pharma Inc. | 2 | $28 |
| Corcept Therapeutics | 2 | $25 |
| Merck | 2 | $25 |
| Insulet Corporation | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Senseonics, Incorporated | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,189
- MINIMED 770G$1,125
- MINIMED 780G$178
How this compares
$18,425 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 187 | $347,280 |
| TrulicityDulaglutide | 204 | $336,460 |
| JardianceEmpagliflozin | 138 | $176,345 |
| OzempicSemaglutide | 88 | $136,390 |
| GenotropinSomatropin | 19 | $90,126 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $89,979 |
| JanuviaSitagliptin Phosphate | 68 | $84,535 |
| FarxigaDapagliflozin Propanediol | 58 | $74,735 |
| RybelsusSemaglutide | 34 | $67,583 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $55,747 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $44,483 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $41,314 |
| SynthroidLevothyroxine Sodium | 339 | $37,712 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 33 | $36,848 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $36,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $43 | $692,390404 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $365 | $226,487171 claims |
| Boehringer IngelheimJardiance, Tradjenta | $13 | $193,001150 claims |
| MerckJanuvia, Janumet | $25 | $114,12295 claims |
| AstraZenecaFarxiga | $30 | $74,73558 claims |
| IBSA Pharma Inc.Tirosint | $28 | $17,00149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Langhorne
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.